BioInvent Interim Report - News, Search Jobs, Events

ClinicaSpace Login

Enter your ClinicaSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

Clinical Research
News & Careers

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
FREE Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Date
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Today's Hot Jobs
Most Recent Jobs
Search Jobs
Post Resume
Career Resources
For Employers

COMMUNITY
Login
Become a Member
FAQ

PROFILES
Company Profiles

INDUSTRY EVENTS
Clinical

RESOURCES
Real Estate
New Business Opportunities

News | News By Subject | News By Date | Search News

Email

BioInvent Interim Report
7/14/2010

LUND, Sweden--(BUSINESS WIRE)-- •Phase II data presented in May shows that the antithrombotic effect of TB-402 is better than enoxaparin, the current standard treatment. •In May BioInvent and ThromboGenics achieved a milestone corresponding to EUR 10 million when development partner Roche launched a new clinical study with the product candidate TB-403. •Reorganisation will give greater focus on the company’s proprietary drug development. Adapted manufacturing capacity to in house needs, reduces fixed costs by around SEK 15 million on an annual basis. •In March BioInvent entered into a partnership with Human Genome Sciences to develop and commercialise therapeutic antibodies. •A directed new share issue that raised SEK 150 million for the company before transaction costs was implemented in February. •Net revenues for January - June 2010: SEK 63.1 million (47.1). •Loss after tax for January - June 2010 amounted to SEK -60.7 million (-88.2) and the loss after tax per share was SEK -1.01 (-1.59). •Current investments together with cash and bank as of 30 June 2010: SEK 138.7 million, excluding share of milestone payments for TB-403 received in July, (150.5). •Cash flow from current operations and investment activities for January – June 2010: SEK -89.7 million (-61.9).

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• BioInvent

• Biotech/Pharma - Earnings

• Clinical - Phase II

• Biotech/Pharma - Investor

• Biotech/Pharma - Earnings (World)

• Biotech/Pharma - Investor (World)

• Clinical - Phase II (World)